2010
DOI: 10.1177/1076029610384112
|View full text |Cite
|
Sign up to set email alerts
|

The Hemostatic System in Patients With Type 2 Diabetes With and Without Cardiovascular Disease

Abstract: The contribution of the hemostatic system in the development of cardiovascular disease (CVD) in patients with type 2 diabetes is not completely defined. The aim of this study was to elucidate associations of hemostatic factors with the development of CVD in patients with type 2 diabetes. Patients with type 2 diabetes without CVD (n ¼ 113), with CVD (n ¼ 94), and controls without CVD (n ¼ 100) were enrolled in this study. Several hemostatic markers were measured. A disturbed hemostatic balance in patients with … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
26
0

Year Published

2010
2010
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 26 publications
(27 citation statements)
references
References 13 publications
1
26
0
Order By: Relevance
“…In accordance with our findings, Verkleij et al. [25] showed an association of hypercoagulability in T2DM patients with cardiovascular disease by the increased levels of prothrombin fragment 1 + 2 (F1 + 2), an indirect estimate of in vivo thrombin generation. Similarly to our results, recently, Tripodi and colleagues [26] could detect hypercoagulability in patients with T2DM by a thrombin generation assay.…”
Section: Discussionsupporting
confidence: 93%
“…In accordance with our findings, Verkleij et al. [25] showed an association of hypercoagulability in T2DM patients with cardiovascular disease by the increased levels of prothrombin fragment 1 + 2 (F1 + 2), an indirect estimate of in vivo thrombin generation. Similarly to our results, recently, Tripodi and colleagues [26] could detect hypercoagulability in patients with T2DM by a thrombin generation assay.…”
Section: Discussionsupporting
confidence: 93%
“…What is more, hyperglycemia is known to cause increased glycation of proteins and this may also occur in proteins involved in coagulation and fibrinolysis. Verkleij et al [7] showed that glycated TAFI loses its fibrinolytic properties in vitro, although this could not be reproduced in vivo. Fibrin clots from patients with diabetes type 2 are denser as compared with controls and displayed an altered structure, resulting in longer clot lysis time [79].…”
Section: Possible Mechanismsmentioning
confidence: 99%
“…Improved glycemic control was the only significant predictor of a decrease in blood thrombogenicity irrespective of treatment allocation [6]. The contribution of hypercoagulability in DM2 to the development of cardiovascular disease was also illustrated by the increased levels of prothrombin fragment 1 + 2 (F1 + 2) found to be associated with the presence of proven cardiovascular disease in DM2 patients as compared with patients without cardiovascular disease [7].…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…Hemostatic imbalance may contribute to the development of cardiovascular disease in patients with type 2 diabetes mellitus. In patients with diabetes mellitus there is a state of hypofibrinolysis and increased levels of vWF 13 . The elevated levels of vWF are correlated with atherosclerosis and are associated with endothelial dysfunction in type 2 diabetes, as well as the development of diabetes in post-infarction patients 14,15 .…”
Section: Introductionmentioning
confidence: 99%